



Technical Report No. 41 (Revised 2022)

Virus Retentive Filtration



Virus Retentive Filtration Team

Authors

Kurt Brorson, PhD, Parexel International, Co-Chair

Scott Lute, U.S. Food and Drug Administration, Co-Chair

Hazel Aranha, PhD, Sartorius-Stedim Biotech

Sherri Dolan, Sartorius-Stedim Biotech S.A.

Sal Giglia, MilliporeSigma

Albrecht Gröner, PhD, PathoGuard Consult

Bjoern Hansmann, PhD, Sartorius-Stedim Biotech

Sibylle Herzer, PhD, Kite Pharma EU B.V.

Daniel LaCasse, Pfizer

Morven McAlister, PhD, Pall Life Sciences

Michael Burdick, PhD, CSL Behring

David Roush, Merck, Sharp & Dohme

Sebastian Teitz, PhD, Asahi Kasei Bioprocess,
Germany

Humberto Vega, PhD, Celgene

Andrew Zydney, PhD, The Pennsylvania State
University

Virus Retentive Filtration

Technical Report No. 41 (Revised 2022)

ISBN: 978-1-945584-34-3

© 2022 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1		
1.1 Purpose	1		
1.2 Scope	1		
2.0 GLOSSARY AND ABBREVIATIONS	2		
2.1 Acronyms	5		
3.0 VIRUS-RETENTIVE FILTERS	5		
3.1 History of Virus Filters and Legacy Products	6		
3.2 Size Exclusion/Other Retention Mechanisms	7		
3.3 Virus Retention or Reduction Factor	8		
3.4 Virus Size/Retention Rating	8		
3.5 Protein Size, Sieving, and Passage Rating	8		
4.0 CONSIDERATIONS FOR VIRUS			
FILTER SELECTION	9		
4.1 Filter Validation/Qualification Expectations	9		
4.2 Filter Construction	9		
4.3 Hydraulic Stress Resistance	9		
4.4 Filter System Configurations	9		
4.5 Particulates, Leachables, and Extractables	11		
4.6 Fluid/Filter Compatibility	11		
4.7 Membrane Symmetry	12		
4.8 Virus/Phage Challenge Testing (Opportunity for Standardization)	12		
4.9 Physical and Structural Limitations	12		
4.10 Thermal / Chemical Stress Resistance	12		
5.0 VIRUS FILTER INTEGRITY TESTS	13		
5.1 Relationship between Integrity Tests and Virus Retention	14		
5.2 Virus Retention Integrity Tests	14		
5.2.1 Gold Particle Retention	16		
5.2.2 Gas-Liquid Diffusion	16		
5.2.3 Automated Integrity Test Instruments for Gas-Liquid-Based Test Methods	18		
5.2.4 Liquid-Liquid Porosimetry	18		
5.3 Integrity Testing Checklist	18		
5.3.1 Failure Analysis/Troubleshooting	19		
5.3.2 Filter Manufacturer Integrity Tests	20		
6.0 VIRUS FILTRATION VALIDATION/ QUALIFICATION STUDIES	20		
6.1 Raw and Starting Materials and Equipment	20		
6.1.1 Virus Filtration Devices and Configurations	21		
6.1.2 Integrity Testing during Development	23		
6.1.3 Filtration Variability	23		
6.1.4 Feed Stream	24		
6.1.5 Filtration Conditions	24		
6.2 Establishing Representative Worst-Case Process Conditions	24		
6.3 Sequence of Process Evaluation	26		
6.3.1 Scale-Down (Design) Qualification: Studies without Virus	26		
6.3.2 Virus Clearance Validation Studies	27		
6.4 Test Virus	27		
6.4.1 Clinical vs. Licensure	28		
6.4.2 Application of Parvovirus Claims to Larger Viruses	28		
6.4.3 Modular Claims	28		
6.4.4 Virus Selection	29		
6.4.5 Virus Spike Considerations	29		
6.5 Operating Conditions for Validation, Revalidation, and Number of Runs	29		
6.5.1 Quality by Design Considerations for Study Design	29		
6.6 Virus Assays and Assay Validation	31		
6.7 Manufacturing-scale Qualification: Studies without Virus	31		
6.8 Failure Analysis/Troubleshooting	31		
7.0 TYPES AND USES OF VIRUS FILTRATION	32		
7.1 Industry Applications and Challenges	32		
7.1.1 Advanced Therapeutic Medicinal Products	33		
7.2 Downstream Processing	33		
7.3 Barrier Filtration of Input Raw Materials	33		
7.3.1 Barrier Filter Requirements	35		
8.0 PHYSICAL AND MECHANICAL CHARACTERIZATION	36		
8.1 Flow Rate and Clogging (Throughput)	36		
9.0 STERILIZATION	37		
10.0 AREAS FOR FURTHER CONSIDERATION	40		
10.1 Introduction of New Filter Types and Configurations	40		
10.2 Facilities Segregation	40		
10.3 Continuous Virus Filtration	41		
10.3.1 Extended Processing Times	42		
10.3.2 Pressure and Fluid Protein Concentration Fluctuation during Processing	42		
10.3.3 Validation Strategies	42		
10.4 Reprocessing	42		
10.5 Process Intensification	43		
11.0 REFERENCES	43		
12.0 APPENDIX I: RISK EVALUATION TOOLS	47		
13.0 APPENDIX II: VIRUS RETENTION AND PROTEIN PASSAGE NOMENCLATURE CLASSIFICATION ...	52		
13.1 References for Appendix II	52		

FIGURES AND TABLES INDEX

Figure 3.0-1	Depiction of the Log10 Reduction Factor (LRF) as a Function of Virus Size 6	Table 6.4.5-1	Virus Stock Considerations 29
Table 4.1-1	Typical Qualification and Validation Test Recommendations for Virus Filters 10	Table 6.5.1-1	Quality by Design Considerations 30
Figure 4.5-1	Examples of NFF and TFF Filtration Systems (Picture courtesy of MilliporeSigma) 11	Table 7.1-1	Potential Points of Use for Biological Product Classes 33
Table 5.2-1	Filter Integrity Test Characteristics... 15	Table 9.0-1	Filter Sterilization Considerations 38
Table 5.3-1	Integrity Testing Considerations 19	Table 10.5-1	Process Intensification Considerations..... 43
Figure 6.1.1.1-1	Schematics of Decoupled (Off-Line) Prefiltration 21	Table 12.0-1	A Simple Risk Assessment Tool with Categorical Impact Levels of High, Medium, and Low 49
Figure 6.1.1.1-2	Schematics of Coupled (In-Line) Prefiltration 22	Table 12.0-2	Overview of Potential Categorization of Factors in a Virus Clearance FMEA 51
Figure 6.1.1.1-3	Schematics of In-Line Spiking 22	Table 12.0-3	Overview of Preset RPN Scores 51
Figure 6.1.1.1-4	Considerations for Inclusion of a Prefilter in a Virus Filter Study 23	Table 12.0-4	Brief Excerpt of a Monoclonal Antibody Platform Process Failure Mode Effect Analysis 52
Table 6.2-1	Operational Factors Affecting Virus Retention 25	Figure 12.0-1	Example of an Ishikawa/fishbone Tool Employed to Analyze Potential Failure Modes for a Phase III 48



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org